| Natural killer cell responses to viral infection JD Brandstadter, Y Yang Journal of innate immunity 3 (3), 274-279, 2011 | 253 | 2011 |
| International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease F Van Rhee, E Oksenhendler, G Srkalovic, P Voorhees, M Lim, ... Blood advances 4 (23), 6039-6050, 2020 | 137 | 2020 |
| Heparan sulfate mimetic PG545-mediated antilymphoma effects require TLR9-dependent NK cell activation TV Brennan, L Lin, JD Brandstadter, VR Rendell, K Dredge, X Huang, ... The Journal of Clinical Investigation 126 (1), 207-219, 2016 | 78 | 2016 |
| Notch signalling in T cell homeostasis and differentiation JD Brandstadter, I Maillard Open biology 9 (11), 190187, 2019 | 65 | 2019 |
| Hematopoietic stem cell transplantation for blood cancers in the era of precision medicine and immunotherapy SM Bair, JD Brandstadter, EC Ayers, EA Stadtmauer Cancer 126 (9), 1837-1855, 2020 | 29 | 2020 |
| NK cell‐extrinsic IL‐18 signaling is required for efficient NK‐cell activation by vaccinia virus JD Brandstadter, X Huang, Y Yang European journal of immunology 44 (9), 2659-2666, 2014 | 19 | 2014 |
| PI16+ reticular cells in human palatine tonsils govern T cell activity in distinct subepithelial niches A De Martin, Y Stanossek, M Lütge, N Cadosch, L Onder, HW Cheng, ... Nature Immunology 24 (7), 1138-1148, 2023 | 11 | 2023 |
| IL-18-dependent NKG2D ligand upregulation on accessory cells is mediated by the PI3K/GSK-3 pathway JD Brandstadter, H Chen, S Jiang, X Huang, Y Yang Journal of Leucocyte Biology 101 (6), 1317-1323, 2017 | 6 | 2017 |
| Natural killer cell responses to viral infection. J Innate Immun. 2011; 3 (3): 274–9 JD Brandstadter, Y Yang Epub 2011/03/18. https://doi. org/10.1159/000324176 PMID: 21411975, 0 | 5 | |
| Treatment consistent with idiopathic multicentric Castleman disease guidelines is associated with improved outcomes SK Pierson, MS Lim, G Srkalovic, JD Brandstadter, ... Blood Advances 7 (21), 6652-6664, 2023 | 4 | 2023 |
| How we manage idiopathic multicentric Castleman disease JD Brandstadter, DC Fajgenbaum Clinical advances in hematology & oncology: H&O 20 (9), 564, 2022 | 4 | 2022 |
| Siltuximab administration results in spurious IL-6 elevation in peripheral blood NA Mango, SK Pierson, MS Bustamante, JD Brandstadter, F van Rhee, ... American journal of hematology 99 (1), E15, 2024 | 3 | 2024 |
| Longitudinal, natural history study reveals the disease burden of idiopathic multicentric Castleman disease MS Bustamante, SK Pierson, Y Ren, A Bagg, JD Brandstadter, ... Haematologica, 2020 | 3 | 2020 |
| Immune‐mediated thrombocytopenia and IL‐6‐mediated thrombocytosis observed in idiopathic multicentric Castleman disease AI Rubenstein, SK Pierson, S Shyamsundar, MS Bustamante, ... British Journal of Haematology 204 (3), 921-930, 2024 | 2 | 2024 |
| Longitudinal, real-world data reveal treatment effectiveness in idiopathic multicentric Castleman disease and support current treatment guidelines SK Pierson, M Sarmiento Bustamante, JD Brandstadter, D Alapat, A Bagg, ... Blood 140 (Supplement 1), 9378-9379, 2022 | 2 | 2022 |
| Differential impact of a dyskeratosis congenita mutation in TPP1 on mouse hematopoiesis and germline JV Graniel, K Bisht, A Friedman, J White, E Perkey, A Vanderbeck, ... Life Science Alliance 5 (1), 2022 | 2 | 2022 |
| Natural killer cell responses to viral infection. J Innate Immun 2011; 3: 274–9 JD Brandstadter, Y Yang | 2 | |
| Patients with Castleman disease report mild COVID-19 symptoms and mount a humoral response to SARS-CoV-2 vaccination S Shyamsundar, SK Pierson, CM Connolly, M Teles, DL Segev, ... Blood Neoplasia 1 (1), 100002, 2024 | 1 | 2024 |
| Ongoing symptoms following complete surgical excision in unicentric Castleman disease MS Bustamante, S Shyamsundar, FR Coren, A Bagg, G Srkalovic, ... American journal of hematology 98 (11), E334, 2023 | 1 | 2023 |
| Increased comorbidities and hospitalizations associated with idiopathic multicentric Castleman disease M Sarmiento Bustamante, SK Pierson, Y Ren, D Alapat, A Bagg, ... Blood 140 (Supplement 1), 6520-6521, 2022 | 1 | 2022 |
